Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 69Gastrointestinal 39Breast 20Gynecologic 13Sarcoma 11Head & Neck 10CNS 8Endocrine 6Genitourinary 5Tumor-Agnostic 4Other solid neoplasm 3NET 2Dermatologic 2

Conditions

Neuroendocrine Tumors 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Digestive System Neoplasms 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × anlotinib × NET × Clear all
NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

NCT03457844 2018-09-11

A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumor G3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡